Sarepta Therapeutics Inc
SRPT16.275USD
-0.145-0.88%
取引時間 （ET）15分遅れの株価
1.60B時価総額
損失額直近12ヶ月PER
詳細情報 Sarepta Therapeutics Inc 企業名
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
企業情報
企業コードSRPT
会社名Sarepta Therapeutics Inc
上場日Jun 04, 1997
設立日2013
最高経営責任者「CEO」Mr. Douglas S. (Doug) Ingram, Esq., J.D.
従業員数1372
証券種類Ordinary Share
決算期末Jun 04
本社所在地215 First Street
都市CAMBRIDGE
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号02142
電話番号16172744000
ウェブサイトhttps://www.sarepta.com/
企業コードSRPT
上場日Jun 04, 1997
設立日2013
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Cristin Rothfuss
Cristin Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
19.15K
+38.59%
Mr. Bilal Arif
Mr. Bilal Arif
Executive Vice President , Chief Technical Operations Officer
Executive Vice President , Chief Technical Operations Officer
16.42K
-16.76%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
事業別USD
会社名
収益
比率
ELEVIDYS
374.99M
50.34%
PMO Products
236.54M
31.76%
collaboration and other
133.33M
17.90%
地域別USD
会社名
収益
比率
United States
560.81M
75.29%
Rest of World
50.71M
6.81%
事業別
地域別
事業別USD
会社名
収益
比率
ELEVIDYS
374.99M
50.34%
PMO Products
236.54M
31.76%
collaboration and other
133.33M
17.90%
株主
更新時刻: Sun, Jul 27
更新時刻: Sun, Jul 27
株主統計
種類
株主統計
株主統計
比率
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
D. E. Shaw & Co., L.P.
5.15%
State Street Global Advisors (US)
4.14%
Other
63.27%
株主統計
株主統計
比率
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
D. E. Shaw & Co., L.P.
5.15%
State Street Global Advisors (US)
4.14%
Other
63.27%
種類
株主統計
比率
Investment Advisor
45.73%
Investment Advisor/Hedge Fund
28.79%
Hedge Fund
14.66%
Individual Investor
4.42%
Research Firm
3.31%
Bank and Trust
1.12%
Pension Fund
1.10%
Sovereign Wealth Fund
1.09%
Venture Capital
0.33%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
1025
94.29M
95.95%
-13.91M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
2023Q1
946
86.41M
92.84%
-2.26M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Capital International Investors
9.06M
9.22%
+363.63K
+4.18%
Mar 31, 2025
The Vanguard Group, Inc.
9.01M
9.17%
-59.02K
-0.65%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
9.06%
-32.03K
-0.36%
Mar 31, 2025
State Street Global Advisors (US)
4.07M
4.14%
-1.39K
-0.03%
Mar 31, 2025
Janus Henderson Investors
3.36M
3.42%
-963.48K
-22.26%
Mar 31, 2025
Barry (Richard J)
3.21M
3.27%
+32.60K
+1.02%
May 16, 2025
Avoro Capital Advisors LLC
2.67M
2.72%
+119.28K
+4.67%
Mar 31, 2025
Wellington Management Company, LLP
2.65M
2.69%
+577.85K
+27.93%
Mar 31, 2025
Farallon Capital Management, L.L.C.
2.34M
2.38%
-523.68K
-18.28%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sun, Jul 6
更新時刻: Sun, Jul 6
銘柄名
比率
Global X Genomics & Biotechnology ETF
2.7%
First Trust NYSE Arca Biotechnology Index Fund
2.31%
iShares Neuroscience and Healthcare ETF
1.71%
WisdomTree BioRevolution Fund
0.92%
Virtus LifeSci Biotech Products ETF
0.91%
Harbor Human Capital Factor Unconstrained ETF
0.87%
VanEck Biotech ETF
0.79%
Tema Neuroscience and Mental Health ETF
0.72%
SPDR S&P Biotech ETF
0.66%
Invesco S&P MidCap 400 Pure Growth ETF
0.54%
詳細を見る
Global X Genomics & Biotechnology ETF
比率2.7%
First Trust NYSE Arca Biotechnology Index Fund
比率2.31%
iShares Neuroscience and Healthcare ETF
比率1.71%
WisdomTree BioRevolution Fund
比率0.92%
Virtus LifeSci Biotech Products ETF
比率0.91%
Harbor Human Capital Factor Unconstrained ETF
比率0.87%
VanEck Biotech ETF
比率0.79%
Tema Neuroscience and Mental Health ETF
比率0.72%
SPDR S&P Biotech ETF
比率0.66%
Invesco S&P MidCap 400 Pure Growth ETF
比率0.54%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
